<DOC>
	<DOCNO>NCT02798211</DOCNO>
	<brief_summary>To demonstrate efficacy secukinumab 300 mg Week 16 superior placebo adult patient active PsA base proportion patient achieve American College Rheumatology 20 ( ACR20 ) response .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Secukinumab 300 mg 150 mg Adult Patients With Active Psoriatic Arthritis ( PsA ) After 16 Weeks Treatment Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male nonpregnant , nonlactating female patient least 18 year age Diagnosis PsA classify CASPAR criterion symptoms least 6 month moderate severe PsA must Baseline ≥3 tender joint 78 ≥3 swell 76 ( dactylitis digit count one joint ) Rheumatoid factor and/or antiCCP antibody negative screen A target skin psoriatic lesion PASI score 1 great Chest Xray evidence ongoing infectious malignant process Patients ever receive biologic immunomodulating agent include target TNFα , IL6 IL12/23 investigational approve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PsA , ACR , CASPAR</keyword>
</DOC>